Title | Author(s) | Issue date | ???itemlist.??? |
Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study | Skarlos, D. V.; Kalofonos, H. P.; Fountzilas, G.; Dimopoulos, M. A.; Pavlidis, N.; Razis, E.; Economopoulos, T.; Pectasides, D.; Gogas, H.; Kosmidis, P.; Bafaloukos, D.; Klouvas, G.; Kyratzis, G.; Aravantinos, G. | 24-Nov-2015 | - |
HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy | Fountzilas, G.; Valavanis, C.; Kotoula, V.; Eleftheraki, A. G.; Kalogeras, K. T.; Tzaida, O.; Batistatou, A.; Kronenwett, R.; Wirtz, R. M.; Bobos, M.; Timotheadou, E.; Soupos, N.; Pentheroudakis, G.; Gogas, H.; Vlachodimitropoulos, D.; Polychronidou, G.; Aravantinos, G.; Koutras, A.; Christodoulou, C.; Pectasides, D.; Arapantoni, P. | 24-Nov-2015 | - |
Ifosfamide plus oral etoposide salvage chemotherapy for platinum-resistant paclitaxel-pretreated ovarian cancer | Aravantinos, G.; Dimopoulos, M. A.; Kosmidis, P.; Bafaloukos, D.; Papadimitriou, C.; Kiamouris, C.; Pavlidis, N.; Sikiotis, K.; Papakostas, P.; Skarlos, D. V. | 24-Nov-2015 | - |
Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer | Kalofonos, H. P.; Papakostas, P.; Makatsoris, T.; Papamichael, D.; Vourli, G.; Xanthakis, I.; Aravantinos, G.; Papadimitriou, C.; Pentheroudakis, G.; Varthalitis, I.; Samelis, G.; Syrigos, K. N.; Xiros, N.; Stavropoulos, M.; Kosmidis, P.; Christodoulou, C.; Linardou, H.; Skondra, M.; Pectasides, D.; Economopoulos, T.; Fountzilas, G. | 24-Nov-2015 | - |
Megestrol acetate in cancer patients with anorexia and weight loss. A Hellenic Co-operative Oncology Group (HeCOG) study | Skarlos, D. V.; Fountzilas, G.; Pavlidis, N.; Beer, M.; Makrantonakis, P.; Aravantinos, G.; Pantelakos, P.; Tsavaris, N.; Karpasitis, N.; Kosmidis, P. | 24-Nov-2015 | - |
Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: a hellenic cooperative oncology group study | Briasoulis, E.; Fountzilas, G.; Bamias, A.; Dimopoulos, M. A.; Xiros, N.; Aravantinos, G.; Samantas, E.; Kalofonos, H.; Makatsoris, T.; Mylonakis, N.; Papakostas, P.; Skarlos, D.; Varthalitis, I.; Pavlidis, N. | 24-Nov-2015 | - |
Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation | Fountzilas, G.; Kourea, H. P.; Bobos, M.; Televantou, D.; Kotoula, V.; Papadimitriou, C.; Papazisis, K. T.; Timotheadou, E.; Efstratiou, I.; Koutras, A.; Pentheroudakis, G.; Christodoulou, C.; Aravantinos, G.; Miliaras, D.; Petraki, K.; Papandreou, C. N.; Papakostas, P.; Bafaloukos, D.; Repana, D.; Razis, E.; Pectasides, D.; Dimopoulos, A. M. | 24-Nov-2015 | - |
Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group | Fountzilas, G.; Kalofonos, H. P.; Dafni, U.; Papadimitriou, C.; Bafaloukos, D.; Papakostas, P.; Kalogera-Fountzila, A.; Gogas, H.; Aravantinos, G.; Moulopoulos, L. A.; Economopoulos, T.; Pectasides, D.; Maniadakis, N.; Siafaka, V.; Briasoulis, E.; Christodoulou, C.; Tsavdaridis, D.; Makrantonakis, P.; Razis, E.; Kosmidis, P.; Skarlos, D.; Dimopoulos, M. A. | 24-Nov-2015 | - |
Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group | Fountzilas, G.; Papakostas, P.; Dafni, U.; Makatsoris, T.; Karina, M.; Kalogera-Fountzila, A.; Maniadakis, N.; Aravantinos, G.; Syrigos, K.; Bamias, A.; Christodoulou, C.; Economopoulos, T.; Kalofonos, H.; Nikolaou, A.; Angouridakis, N.; Stathopoulos, G.; Bafaloukos, D.; Pavlidis, N.; Daniilidis, J. | 24-Nov-2015 | - |
Paclitaxel by 3-h infusion and carboplatin in anthracycline-resistant advanced breast cancer. A phase II study conducted by the Hellenic Cooperative Oncology Group | Fountzilas, G.; Athanassiadis, A.; Kalogera-Fountzila, A.; Aravantinos, G.; Bafaloukos, D.; Briasoulis, E.; Dombros, N.; Ioannidis, I.; Pavlidis, N.; Kosmidis, P.; Skarlos, D. | 24-Nov-2015 | - |
Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study | Aravantinos, G.; Fountzilas, G.; Kosmidis, P.; Dimopoulos, M. A.; Stathopoulos, G. P.; Pavlidis, N.; Bafaloukos, D.; Papadimitriou, C.; Karpathios, S.; Georgoulias, V.; Papakostas, P.; Kalofonos, H. P.; Grimani, E.; Skarlos, D. V. | 24-Nov-2015 | - |
Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study | Skarlos, D. V.; Aravantinos, G.; Kosmidis, P.; Athanassiadis, A.; Stathopoulos, G. P.; Pavlidis, N.; Bafaloukos, D.; Karphathios, S.; Papakostas, P.; Bamia, C.; Fountzilas, G. | 24-Nov-2015 | - |
Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors | Pentheroudakis, G.; Fountzilas, G.; Kalofonos, H. P.; Golfinopoulos, V.; Aravantinos, G.; Bafaloukos, D.; Papakostas, P.; Pectasides, D.; Christodoulou, C.; Syrigos, K.; Economopoulos, T.; Pavlidis, N. | 24-Nov-2015 | - |
Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic Cooperative Oncology Group | Skarlos, D. V.; Timotheadou, E.; Galani, E.; Samantas, E.; Grimani, I.; Lianos, E.; Aravantinos, G.; Xanthakis, I.; Pentheroudakis, G.; Pectasides, D.; Fountzilas, G. | 24-Nov-2015 | - |
Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer | Aravantinos, G.; Bafaloukos, D.; Fountzilas, G.; Christodoulou, C.; Papadimitriou, C.; Pavlidis, N.; Kalofonos, H. P.; Gogas, H.; Kosmidis, P.; Dimopoulos, M. A. | 24-Nov-2015 | - |
A phase III study of 5-fluorouracil versus 5-fluorouracil plus interferon alpha 2b versus 5-fluorouracil plus leucovorin in patients with advanced colorectal cancer: a Hellenic Cooperative Oncology Group (HeCOG) study | Kalofonos, H. P.; Nicolaides, C.; Samantas, E.; Mylonakis, N.; Aravantinos, G.; Dimopoulos, M. A.; Gennatas, C.; Kouvatseas, G.; Giannoulis, E.; Dervenis, C.; Basdanis, G.; Pavlidis, N.; Androulakis, I.; Fountzilas, G. | 24-Nov-2015 | - |
Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group | Fountzilas, G.; Skarlos, D.; Dafni, U.; Gogas, H.; Briasoulis, E.; Pectasides, D.; Papadimitriou, C.; Markopoulos, C.; Polychronis, A.; Kalofonos, H. P.; Siafaka, V.; Kosmidis, P.; Timotheadou, E.; Tsavdaridis, D.; Bafaloukos, D.; Papakostas, P.; Razis, E.; Makrantonakis, P.; Aravantinos, G.; Christodoulou, C.; Dimopoulos, A. M. | 24-Nov-2015 | - |
Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human Erythropoietin (rHuEpo): a prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group | Bamias, A.; Aravantinos, G.; Kalofonos, C.; Timotheadou, N.; Siafaka, V.; Vlahou, I.; Janinis, D.; Pectasides, D.; Pavlidis, N.; Fountzilas, G. | 24-Nov-2015 | - |
Prognostic significance of HER-2, p53 and Bcl-2 in patients with epithelial ovarian cancer | Malamou-Mitsi, V.; Crikoni, O.; Timotheadou, E.; Aravantinos, G.; Vrettou, E.; Agnantis, N.; Fountzilas, G. | 24-Nov-2015 | - |
Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A Hellenic Cooperative Oncology Group (HeCOG) Study | Psyrri, A.; Kalogeras, K. T.; Kronenwett, R.; Wirtz, R. M.; Batistatou, A.; Bournakis, E.; Timotheadou, E.; Gogas, H.; Aravantinos, G.; Christodoulou, C.; Makatsoris, T.; Linardou, H.; Pectasides, D.; Pavlidis, N.; Economopoulos, T.; Fountzilas, G. | 24-Nov-2015 | - |